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The time-course for the development of ultraviolet
A-induced erythema in psoralen-sensitized skin differs
from that caused by ultraviolet B or ultraviolet A
but objective data are not available. During psoralen
ultraviolet A therapy, the minimal phototoxic dose
is determined 72 h after exposure, when psoralen
ultraviolet A erythema is assumed to be maximal.
This measurement is of fundamental importance in
optimizing the therapeutic regimen. We examined
a detailed time-course for development of psoralen
ultraviolet A erythema in 16 subjects. The erythemal
responses to ultraviolet B, ultraviolet A and psoralen
ultraviolet A were assessed visually and using a
reflectance device. Ultraviolet B erythema was
maximal 24 h after exposure compared with sub-
sequent time-points. Psoralen ultraviolet A erythema
was evident at 24 h, with reduction in the median
ultraviolet A minimal erythema dose from 14 to 5 J
per cm2 in the presence of psoralen (p < 0.01; n J 9).
During psoralen and ultraviolet A (PUVA) therapy,for example when treating psoriasis, it is the potentialfor erythema development in nonlesional skin thatlimits the dose of UVA that can be given ateach treatment. The time-course and dose–response
characteristics of PUVA erythema are therefore of fundamental
importance when attempting to design an optimal treatment
regimen.
The time-course for development of UVA-induced erythema in
psoralen-sensitized skin is known to be different from that resulting
from exposure to UVB or UVA alone. PUVA erythema is said to
appear at 24 h after exposure and peak between 48 and 72 h after
irradiation (Fitzpatrick et al, 1955; Parrish, 1976; Pathak et al, 1976;
Frain-Bell, 1985; Gupta and Anderson, 1987), although there are
little experimental data to support this. In this study we report the
first detailed examination of the time-course for the development
of PUVA erythema.
MATERIALS AND METHODS
Subjects We studied 16 healthy adults (12 female; median age 33 y;
range 21–74) of skin types I (n 5 2), II (n 5 11), and III (n 5 3). None
of the subjects had a history of abnormal sunlight sensitivity, and none
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Peak psoralen ultraviolet A erythema, assessed by
minimal phototoxic dose, did not occur until 96 h
or later in 75% of subjects. Using individual dose–
response curves, we determined that only 67% of mean
maximum psoralen ultraviolet A erythemal intensity
had developed by 72 h. Furthermore, at the time of
maximal erythema, the slope of the psoralen ultra-
violet A dose–response curve was approximately 2-
fold shallower than that for ultraviolet B-induced
erythema. If assessment of psoralen ultraviolet A
erythemal sensitivity had been made at 96 h instead
of the conventional 72 h time-point, peak erythemal
responses would not have been missed in any of the
subjects. Based on these findings, it seems appropriate
to consider whether psoralen ultraviolet A minimal
phototoxic dose measurements should be performed
96 h after exposure. Key words: dose-response curve/
irradiation monochromator/minimal phototoxic dose/peak
erythema/slope. J Invest Dermatol 113:346–349, 1999
were receiving medication or UV therapy. The responses of each subject
to UVB, UVA, and PUVA were measured on the untanned normal skin
of the mid-back.
Photoirradiation apparatus An irradiation monochromator (Diffey
et al, 1984a), optically coupled to a liquid-filled light guide, was used to
achieve a uniform irradiation field of 1 cm diameter.
UVB phototesting Seven sites on one side of the back were exposed
to a geometric series of doses at 300 6 5 nm (dose range 10–80 mJ per
cm2, increment factor 1.4).
UVA phototesting Nine sites on the opposite side of the back were
exposed to a geometric series of doses at 350 6 30 nm (dose range 1.7–
28 J per cm2, increment factor 1.4).
PUVA phototesting Two hours after ingestion of methoxsalen
(Crawford Pharmaceuticals, Milton Keynes, U.K.) at a standard dose of
25 mg per m2, calculated to the nearest 10 mg (Sakuntabhai et al, 1995),
11 sites adjacent to the UVA test sites, were exposed to a geometric series
of doses at 350 6 30 nm (dose range 0.45–14 J per cm2, increment factor
1.4). Under these conditions, the spectral power distribution of the
irradiation monochromator approximates that of a typical PUVA-type UVA
fluorescent lamp (e.g., Philips TL-09) (Sakuntabhai et al, 1993a). For
comparison, 0.28% of the UV energy is less than or equal to 320 nm
(UVB) for the monochromator and 1.03% for the TL-09 source. The high
irradiance achieved with the irradiation monochromator (µ120 mW per
cm2), however, allowed considerably shorter exposure times than would
have been required had a conventional PUVA lamp been used for
phototesting.
Erythemal response The minimal erythema dose (MED), or the
minimal phototoxic dose (MPD), in the presence of psoralen sensitization,
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Figure 1. An example of a dose–response curve for PUVA erythema
in one subject. Each point represents the mean 6 SD increase (∆E) in
erythema index compared with unirradiated sites. The line drawn through
the data points is the logit function obtained by regression analysis. The
D0.025 (as indicated) is the dose of radiation required to cause an increase
in erythema index of 0.025.
was defined as the smallest dose of radiation to achieve faint but easily
discernible erythema. The MED and MPD values were judged visually at
24, 48, 72, 96, 144, and 168 h (7 d) after irradiation. Any increase in
melanin pigmentation was detected by blanching the irradiated skin. At all
time-points until increased pigmentation was detected, erythema was also
measured objectively using a reflectance instrument (Diffey et al, 1984b).
Erythema measurements were made in triplicate at each irradiated site, and
at adjacent nonirradiated sites. In each subject, for each quality of radiation
(UVB, UVA and PUVA), and at each time of measurement (until
pigmentation was apparent), the increase (∆E) in mean erythema index
compared with nonirradiated skin was plotted against the logarithm of the
UV radiation dose. A logit function was fitted to the data to construct
dose–response curves (Diffey and Farr, 1991) for the different wavebands,
at each time-point, and in each subject. The dose of radiation required to
cause an increase in erythema index of 0.025 (D0.025), clinically equivalent
to just perceptible erythema (MED/MPD), and also the maximum slope,
was calculated for each dose–response curve (Fig 1).
Statistical analysis Values are given as median (range). The significance
of the data was determined by Wilcoxon-matched-pairs signed-rank test.
RESULTS
Time-course UVB responses were measured in eight subjects.
UVB erythema was maximal (lowest MED and D0.025 values) in
all subjects at the first assessment 24 h after exposure, compared with
subsequent time-points, with the intensity of erythema subsequently
declining at a variable rate (Fig 2). UVA erythemal responses were
measured in nine subjects. The MED was recorded at 24 h in all
cases, but too few of the irradiated sites were erythematous to
allow dose–response curves to be constructed. Pigmentation was
apparent at the UVA irradiated sites in the majority of subjects at
72 h and at subsequent time-points. PUVA erythema responses
were measured in nine subjects from 24 to 96 h, and in a further
seven subjects at 72 and 96 h. Erythema was apparent 24 h after
irradiation, with the MPD and D0.025 values then decreasing
stepwise, reaching a minimum at 96 h (Fig 3). Measurements at
subsequent time-points of 144 h (n 5 6) and 168 h (n 5 12)
showed no further overall significant increase in erythemal intensity,
although the 168 h MPD value in one subject was lower than that
at 96 h. Assessment of erythema at 144 h or beyond, however,
was interpreted with caution because of the development of
pigmentation at PUVA irradiated sites.
Effect of psoralen 24 h after UVA irradiation At 24 h after
exposure, in the presence of methoxsalen, the median UVA minimal
Figure 2. Maximal UVB erythema had been reached 24 h after
irradiation. (a) The UVB MED was at a minimum 24 h after exposure
compared with subsequent time-points (median 22 mJ per cm2; range
14–40). (b) The D0.025 was also at a minimum at 24 h [28 (16–39) mJ per
cm2] compared with values at 48 h [31 (18–46) mJ per cm2] or subsequent
time-points (p 5 0.01; n 5 8). The median values at each time-point are
indicated by arrows.
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Figure 3. PUVA erythema was maximal 96 h after irradiation. (a) The
MPD at 96 h [median 0.9 (range 0.6–2.5) J per cm2] was significantly lower
than that at 72 h [1.2 (0.8–3.5) J per cm2] (p , 0.01; n 5 16). (b) The median
D0.025 was also at a minimum at 96 h [0.9 (0.3–3.4) J per cm
2] and was
significantly lower than that at 72 h [1.8 (0.6–4.8) J per cm2] (p , 0.01; n 5
16). The median values at each time-point are indicated by arrows.
Figure 4. The effect of psoralen was apparent 24 h after irradiation.
The median UVA MED (no methoxsalen) was reduced from 14 (range
10–24) J per cm2 to an MPD of 5 (1.7–9) J per cm2 in the presence of
methoxsalen, 24 h after exposure (p , 0.01; n 5 9). The median UVA
MED and PUVA MPD values are indicated by arrows.
erythema response was reduced from 14 (range 10–24) J per cm2
to 5 (1.7–9) J per cm2 (p , 0.01; n 5 9) (Fig 4).
Dose–response curves for UVB and PUVA erythema The
maximum slope of the dose–response was significantly steeper for
erythema induced by UVB (measured at 24 h) (median slope 411,
range 262–826) compared with erythema induced by PUVA
measured at 72 h (median 227, range 90–407) or 96 h (median
225, range 76–460) (p , 0.05; n 5 8).
DISCUSSION
Contrary to previous reports (Fitzpatrick et al, 1955) we have
shown that PUVA erythema is well-established 24 h after exposure,
with the UVA dose required to achieve a minimal erythema
response reduced, on average, by 64% in the presence of psoralen.
UVB erythema was maximal at the first assessment time, 24 h after
irradiation, compared with subsequent measurements. This concurs
with the findings of previous work in which peak UVB erythema
had been reached by 24 h (Farr et al, 1988). Similarly, UVA
erythema was at a peak at 24 h, with the reaction either fading or
being replaced by pigmentation at subsequent time-points. In
contrast, the intensity of PUVA erythema increased at each time-
point, first reaching a maximum (i.e., lowest minimal phototoxic
dose) by 72 h in four of 16 (25%) subjects and by 96 h or later, in
the remainder (75%). If the erythema measurements had been made
at 96 h, peak erythemal responses, based on MPD measurements,
would not have been missed in any of the subjects studied.
Observations up to 7 d after exposure showed no further significant
increase in sensitivity.
Minimal erythema is widely used as an end-point for the
assessment of erythema in both the clinical and research setting;
however, it is somewhat subjective, and imprecise. Also, it may be
surprisingly difficult to judge which site, in a series exposed to
increasing doses of radiation, is the first to show ‘‘just detectable
erythema’’. This is even more problematic when small dose
increments are used in an attempt to improve the precision of the
MED/MPD measurement. In order to overcome these problems
we made objective reflectance measurements of the intensity of
erythema at each irradiated site, in addition to the visual assessment
of minimal erythema. A logit function was computer-fitted to these
data (Diffey and Farr, 1991), resulting in an UV-dose erythema–
response curve for each patient, at each time of observation, for
both PUVA and UVB. From these individual curves we chose to
calculate the dose of radiation required to cause an increase in
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erythema index of 0.025 (D0.025). This degree of erythema is
approximately equivalent to that which can be just detected visually
(Diffey and Farr, 1991), and therefore the D0.025 can be considered
as an objective equivalent of the MED or MPD. The low MED,
MPD, and D0.025 values found in this study reflected the skin type
distribution of the volunteers studied (81% were of skin types I
and II). The D0.025 measurements confirmed the prolonged time-
course of PUVA erythema. If the 96 h erythemal response is
considered to be 100%, then the mean intensity of PUVA erythema
at other time-points would be 31% at 24 h, 59% at 48 h, and 67%
at 72 h.
In addition to the D0.025, we also calculated the maximum slope
for each dose–response curve. This parameter gives an indication
of the rate at which the intensity of erythema increases once doses
of radiation are used in excess of those required to produce minimal
erythema. As might be expected, susceptibility to burning in the
clinical setting is related to the steepness of an individual patient’s
erythema dose–response curve (Sakuntabhai et al, 1993b). We have
confirmed our previous observation (Cox et al, 1989) that PUVA
erythema has a shallower dose–response curve than UVB erythema
(by a factor of µ 2) and have shown that this difference is
maintained even at the time of maximum erythema determined in
this study (24 h for UVB and 96 h for PUVA).
Our results are at variance with previous reports (Fitzpatrick
et al, 1955; Parrish, 1976; Pathak et al, 1976; Morison et al, 1977;
Wolff et al, 1977; Frain-Bell, 1985; Gupta and Anderson, 1987;
British Photodermatology Group, 1994) which suggest that PUVA
erythema reaches a maximum at about 48–72 h after irradiation.
Statements on the time-course of PUVA erythema, however, are
usually unreferenced and very little experimental data have been
published. Likewise, it is often stated without supporting evidence
(Morison et al, 1977; Parrish et al, 1982; Gupta and Anderson,
1987) that the erythema dose–response curve for PUVA is steep
whereas, in fact, our results show that it is considerably shallower
than that for UVB erythema.
During PUVA therapy, for example when treating psoriasis, it is
the potential for erythema development in nonlesional skin that
limits the dose of UVA that can be given at each treatment (Speight
and Farr, 1994). The time-course and dose–response characteristics
of PUVA erythema are therefore of fundamental importance. It is
recommended (British Photodermatology Group, 1994) that the
UVA dose given at the start of PUVA therapy should be based on the
MPD (for example, 70% of the MPD). The MPD is conventionally
measured 72 h after irradiation (Wolff et al, 1977; Carabott and
Hawk, 1989; Sakuntabhai et al, 1993b), at a time when our results
show that the response is not maximal. Using the dose–response
curves it was possible to model the effect of giving 70% of the
MPD measured at different times after irradiation. For example,
we could calculate for each subject the intensity of erythema that
would have resulted at 48 h and at 96 h from a UVA dose of 70%
of the 72 h D0.025. If the erythemal response had been assessed at
the conventional time, 72 h after first exposure, and 70% of this
dose had been given as first treatment, 10 (63%) of the subjects
would have developed visible erythema (i.e., ∆E . 0.025) at some
time between 48 and 96 h. If the MPD had been assessed at 96 h
and 70% of this dose given as first treatment, however, only one
subject (6%) would have developed visible erythema at any time
between 48 and 96 h. In the light of these findings it seems
appropriate to consider whether the PUVA MPD assessment should
be performed 96 h after first exposure and the dosage regimen
based on this reading.
Our observations indicate that treatment given even as
infrequently as twice weekly may incur the risk of development
of cumulative erythema as the interval of 72 h will result in the
patient being re-treated before maximal erythema from the previous
exposure has occurred. Treatment intervals of 96 h or greater would
minimize the risk of missed treatments due to the development of
erythema, although therapeutic efficacy with this regimen would
need to be examined.
Finally, it should be noted that our results apply to erythema
induced after sensitization of the skin using methoxsalen given
orally. The dose–response characteristics and time-course of
erythema induced after topical application of psoralen may be
quite different.
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